Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Interest Expenses (2016 - 2026)

Aytu Biopharma has reported Interest Expenses over the past 13 years, most recently at $560000.0 for Q4 2025.

  • Quarterly Interest Expenses fell 48.1% to $560000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, down 40.96% year-over-year, with the annual reading at $3.7 million for FY2025, 26.8% down from the prior year.
  • Interest Expenses was $560000.0 for Q4 2025 at Aytu Biopharma, up from $516000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $1.3 million in Q3 2023 and troughed at $516000.0 in Q3 2025.
  • The 3-year median for Interest Expenses is $1.0 million (2024), against an average of $983800.0.
  • Year-over-year, Interest Expenses fell 14.77% in 2024 and then tumbled 48.1% in 2025.
  • A 3-year view of Interest Expenses shows it stood at $1.3 million in 2023, then fell by 14.77% to $1.1 million in 2024, then plummeted by 48.1% to $560000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Interest Expenses are $560000.0 (Q4 2025), $516000.0 (Q3 2025), and $730000.0 (Q2 2025).